Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
NPJ Breast Cancer|August 26, 2017
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancerCorey Speers, Shuang G Zhao, Ben Chandler, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Nature|April 25, 2014
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerIrfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, et al.
The Journal of Clinical Investigation|December 22, 2012
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypesMichael A Augello, Craig J Burd, Ruth Birbe, et al.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
NPJ Breast Cancer|March 11, 2022
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer modelsAnna R Michmerhuizen, Lynn M Lerner, Andrea M Pesch, et al.
Cancer & Metabolism|April 9, 2024
Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline gliomaErik R Peterson, Peter Sajjakulnukit, Andrew J Scott, et al.
Research Square|October 4, 2023
Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline gliomaErik R Peterson, Peter Sajjakulnukit, Andrew J Scott, et al.
The Journal of Clinical Investigation|January 22, 2020
TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombinationBenjamin C Chandler, Leah Moubadder, Cassandra L Ritter, et al.
Pageof 5